Loading organizations...
§ Private Profile · Tel Aviv, Tel Aviv, Israel
CHLOE AI decision support tools for IVF clinics. Transparent insights into embryo viability, improving treatment outcomes.
Based in Tel Aviv, Israel, Fairtility develops artificial intelligence-based decision support software for in vitro fertilization clinics and reproductive professionals worldwide. The company's primary software-as-a-service platform, CHLOE EQ, analyzes clinical and laboratory data to provide embryologists with transparent, data-driven insights into embryo viability. By automating the traditional embryo grading process, this technology enables clinic staff to work up to 60 percent faster while reducing the total number of fertilization cycles required to achieve a live birth. Operating with a workforce of 36 employees and generating under $5 million in annual revenue, the enterprise has secured $18.5 million in Series A venture capital funding to expand its suite. The organization's financial growth is supported by institutional backers and venture capital investors, including TAL Ventures. Fairtility was established in 2019 by founder and chief executive officer Eran Eshed.
Fairtility has raised $15.0M across 1 funding round.
Fairtility has raised $15.0M in total across 1 funding round.
Fairtility has raised $15.0M in total across 1 funding round.
Fairtility's investors include Sophie P. Kornowski, Pharm. D, MBA, B Capital Group, Scott Gazelle, Howard Morgan.
Fairtility has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series A in May 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2022 | $15M Series A | Sophie P. Kornowski, Pharm. D, MBA | B Capital Group, Scott Gazelle, Howard Morgan | Announced |
Fairtility is a Tel Aviv-based technology company founded in 2020 that develops transparent AI tools for in vitro fertilization (IVF) clinics, primarily through its CHLOE suite.[1][2] CHLOE provides decision support by analyzing embryo images, oocyte potential, and lab performance metrics, serving fertility clinics worldwide to improve IVF success rates, operational efficiency, and patient transparency—addressing high failure rates, emotional strain, and resource demands in IVF treatments.[2][3] The platform has gained traction with FDA clearance for CHLOE's embryo assessment capabilities and deployment across 100 global clinics, boosting lab efficiency by up to 60% and developer productivity by 50% via Google Cloud infrastructure.[3][5]
Fairtility emerged from a team blending clinical IVF expertise, high-tech entrepreneurship, and software development, driven by the need to demystify IVF through data-driven insights.[2][4] Co-founded in 2020 by CEO Eran Eshed and others—including reproductive endocrinologists from Boston IVF/Harvard and Embryotools directors—the idea stemmed from personal experiences as IVF patients and professionals witnessing subjective embryo selection limitations.[1][4][6] Early momentum included building CHLOE EQ™, trained on millions of data points for embryo quality assessment, rapid global scaling with Google Cloud for remote deployments, and FDA clearance for AI embryo analysis, marking pivotal validation in a field ripe for tech disruption.[3][5]
Fairtility stands out in AI-driven fertility tech through these key strengths:
Fairtility rides the convergence of AI in digital health and surging global IVF demand, fueled by rising infertility rates (affecting 1 in 6 couples) and tech adoption in reproductive medicine.[1][2] Its timing aligns with post-2020 AI advancements in image analysis and regulatory nods like FDA clearance, enabling consistent embryo selection amid clinician shortages and subjective grading pitfalls.[3][5] Market tailwinds include expanding fertility tourism, clinic digitization, and investor interest in health AI—positioning Fairtility to influence standards, as seen in its leadership at the first AI Fertility World Conference.[6] By prioritizing transparency, it pushes the ecosystem toward ethical, accountable AI, potentially reducing IVF cycles needed for live births and democratizing access via remote scalability.[2][3]
Fairtility is primed to expand CHLOE across the full IVF journey—from infertility diagnostics to transfer optimization—leveraging its FDA foothold and global footprint for deeper clinic penetration.[2][5][6] Trends like multimodal AI (integrating genomics/imaging) and personalized medicine will amplify its edge, especially as IVF markets grow to $30B+ amid aging populations and fertility preservation booms.[1][3] Its influence may evolve into industry-wide protocols for transparent AI, drawing more partnerships (e.g., Google Cloud expansions) while navigating data privacy hurdles—ultimately transforming IVF from art to precision science, much like its founding mission to "bring technology to life."[2][4]